только для медицинских специалистов
Консультант врача. Электронная медицинская библиотека

Консультант врача

Электронная медицинская библиотека

Доступ к библиотеке Версия для слабовидящих
Раздел 6 / 6
Страница 1 / 1

Список литературы

  1. Марова ЕИ, Арапова СД, Белая ЖЕ и др. Болезнь Иценко-Кушинга: клиника, диагностика, лечение. Москва. 2012; стр 64.
  2. Nieman LK, Biller BMK, Finding JW et al. The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline. Clin Endocrinol Metab. 2008;93:1526-1540. doi: 10.1210/jc.2008-0125.
  3. Biller BM, Grossman AB, Stewart PM et al. Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. Clin Endocrinol Metab. 2008;93:2454-2462 doi: 10.1210/jc.2007-2734.
  4. Etxabe J, Vazguez JA. Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol (Oxf). 1994;40:479-484.
  5. Plotz D, Knowlton AI, Ragan C. The natural history of Cushing’s disease. Am J. Med. 1952;13:597-614.
  6. O’Riordain DS, Farley DR, Young WF Jr et al. Long-term outcome of bilateral adrenalectomy in patients with Cushing’s syndrome. Surgery. 1994;116:1088-1093.
  7. Clyton RN. Mortality in Cushing’s disease. Neuroendocrinology. 2010;92(1):71-76. doi: 10.1159/000315813.
  8. Pivonello R, Melnichenko G, Zacharieva S et al. Mission study: an international observational study on the mortality in Cushing’s syndrome. Endocrine Abstracts. 2011;26:32.
  9. Белая ЖЕ. Ранняя диагностика эндогенного гиперкортицизма. Канонический wnt сигнальный путь и изменение костного метаболизма при глюкокортикоидном остеопорозе. Диссертация на соискание ученой степени доктора медицинских наук. Москва. 2013;293.
  10. Белая ЖЕ, Рожинская ЛЯ, Драгунова НВ и др. Метаболические осложнения эндогенного гиперкортицизма. Выбор пациентов для скрининга. Ожирение и Метаболизм. 2013;(1):29-34.
  11. Valasi E, Santos A, Yaneva M et al. The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. European J Endocrinology. 2011;165:383-392. doi: 10.1530/EJE-11-0272.
  12. Trifanescu R, Carsote M, Caragheorgheopol A et al. Screening for secondary endocrine hypertension in young patients. Maedica (Buchar). 2013 Jun;8(2):108-115.
  13. Omura M, Saito J, Yamaguchi K et al. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res. 2004;27:193-202.
  14. Catagri B, Rigaleau V, Poussin A et al. Occult Cushing’s syndrome in type- 2 diabetes. Clin Endocrinol Metab. 2003 Dec;88:5808-5813.
  15. Leibowitz G, Tsur A, Chayen SD et al. Pre-clinical Cushing’s syndrome an unexpected frequent cause of poor glycaemic control in obese diabetic patients. Clin Endocrinol (Oxf). 1996;44:717-722.
  16. Terzolo M, Reimondo G, Chiodini I et al. Screening of Cushing's syndrome in outpatients with type 2 diabetes: results of a prospective multicentric study in Italy. Clin Endocrinol Metab. 2012 Oct;97(10):3467- 3475 doi: 10.1210/jc.2012-1323.
  17. Gungunes A, Sahin M, Demirci T et al. Cushing's syndrome in type 2 diabetes patients with poor glycemic control. Endocrine. 2014 Dec;47(3):895-900. doi: 10.1007/s12020-014-0260-8.
  18. Антоненко МИ. Гиперкортицизм без специфических клинических симптомов: этиология, клиника, диагностика. Диссертация на соискание ученой степени кандидата медицинских наук. Ростов-на- Дону. 2014;141.
  19. Волкова НИ, Антоненко МИ, Ганенко ЛА. Первые данные по клинически скрытому синдрому Кушинга у больных сахарным диабетом 2 типа в России. Врач-аспирант. 2013;59(4.2):299-305.
  20. Chiodini I, Mascia ML, Muscarella S et al. Subclinical hypercortisolism among outpatients referred for osteoporosis. Ann Intern Med. 2007;147:541- 548
  21. Moran C, Tapia MC, Hemandez E et al. Etiological review of hirsutism in 250 patients. Arch Med Res. 1994;25:311-314
  22. Diez-Perez A, Hooven FH, Adachi JD et al. Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone. 2011;49:493-498. doi: 10.1016/j.bone.2011.05.007.
  23. van Staa TP, Leufkens HG, Abenhaim L et al. Use of oral corticosteroids in the United Kingdom. QJM. 2000;93:105–111.
  24. Дедов ИИ. Клиническая нейроэндокринология. М. УП Принт. 2011. 343 стр,
  25. Дедов ИИ, Мельниченко ГА, Фадеев ВВ. Эндокринология, учебник. Москва. 2000.
  26. Guechot J, Fiet J, Passa P et al.Physiological and pathological variations in saliva cortisol. Hormone Research. 1982;16:357-364.
  27. Kahn JP, Rubinov DR, Davis CL et al. Salivary cortisol: a practical method for evaluation of adrenal function. Biological Psychiatry. 1988;23:335-349.
  28. Raff H, Raff JL, Finding JW. Late-night salivary cortisol as a screening test for Cushing’s syndrome. Clin Endocrinol Metab. 1998;83:2681-2686.
  29. Raff H. Cushing’s syndrome: diagnosis and surveillance using salivary cortisol. Pituitary. 2012;15:64-70. doi: 10.1007/s11102-011-0333-0.
  30. Kivlighan KT, Granger DA, Schwartz EB, et al. Quantifying blood leakage into the oral mucosa and its effects on the measurement of cortisol, dehydroepiandrosterone, and testosterone in saliva. Horm Behav. 2004;46:39-46.
  31. Smith RE, Maquire JA, Stein-Oakley AN et al. Localization of 11β- hydroxisteroid dehydrogenase type II in human epithelial tissues Clin Endocrinol Metab. 1996;81:3244-3248.
  32. Badrick E, Kirschbaum C, Kumari M. The relationship between smoking status and cortisol secretion. Clin Endocrinol Metab. 2007;92:819-824.
  33. Erickson D, Natt N, Nippoldt T et al. Dexamethasone-suppresed corticotrophin-releasing hormone stimulation test for diagnosis of mild hypercortisolism. Clin Endocrinol Metab. 2007;92:2972-2976.
  34. Gatta B, Chabre O, Cortet C et al. Reevaluation of the combined dexamethasone suppression-corticotropin-releasing hormone test for differentiation of mild Cushing’s disease from pseudo-Cushing’s syndrome. Clin Endocrinol Metab. 2007;92:4290-4293.
  35. Martin NM, Dhillo WS, Banerjee A et al. Comparison of the dexamethasone-suppressed corticotrophin-releasing hormone test and low- dose dexamethasone suppression test in the diagnosis of Cushing’s syndrome. Clin Endocrinol Metab. 2006;91:2582-2586.
  36. Pecori Giraldi F, Pivonello R, Ambrogio AG et al. The dexamethasone- suppressed corticotrophin-releasing hormone stimulation test and the desmopressin test to distinguish Cushing’s syndrome from pseudo- Cushing’s states. Clin Endocrinol (Oxf). 2007;66:251-257.
  37. Magiakou MA, Mastorakos G, Oldfield EH et al. Cushing’s syndrome in children and adolescents. Presentation, diagnosis, and therapy. N Engl J Med. 1994;331:629-636.
  38. Yanovski JA, Cutler GB, Jr. Chrousos GP, Nieman LK. Corticotropin- releasing hormone stimulation following low-dose dexamethasone administration. A new test to distinguish Cushing’s syndrome from pseudo- Cushing’s states. JAMA. 1993;269:2232-2238.
  39. Белая ЖЕ, Ильин АВ, Мельниченко ГА и др. Автоматизированный электрохемилюминисцентный метод определения кортизола в слюне для диагностики эндогенного гиперкортицизма среди пациентов с ожирением. Ожирение и метаболизм. 2011;27(2):56-63.
  40. Wood PJ, Barth JH, Freedman DB et al. Evidence for the low dose dexamethasone suppression test to screen for Cushing’s syndrome – recommendations for a protocol for biochemistry laboratotories. Ann Clin Biochem. 1997;34(Pt3):222-229.
  41. Kidambi S, Raff H, Finding JW. Limitation of nocturnal salivary cortisol and urine free cortisol in the diagnosis of mild Cushing’s syndrome. European J Endocrinology. 2007;157:725-731.
  42. Putigano S, Toja P, Dubini A et al. Midnight salivary cortisol versus urinary free and midnight serum cortisol as screening tests for Cushing’s syndrome. Clin Endocrinol Metab. 2003;88:4153-4157.
  43. Reimondo G, Allasino B, Bovio S et al. Evaluation of the effectiveness of midnight serum cortisol in the diagnostic procedures for Cushing’s syndrome. Eur J Endocrinol. 2005;153:803-809.
  44. Белая ЖЕ, Рожинская ЛЯ, Мельниченко ГА и др. Возможности маркёра костного обмена – остеокальцина – для диагностики эндогенного гиперкортицизма и вторичного остеопороза. Остеопороз и Остеопатии. 2011;(2):7-10.
  45. Sereg M, Toke J, Patocs A et al. Diagnostic performance of salivary cortisol and serum osteocalcin measurements in patients with overt and subclinical Cushing’s syndrome. Steroids. 2011;76:38-42. doi: 10.1016/j.steroids.2010.08.007.
  46. Manenschijn L, Koper JW, van den Akker EL et al. A novel tool in the diagnosis and follow-up of (cyclic) Cushing’s syndrome: measurement of long-term cortisol in scalp hair. Clin Endocrinol Metab. 2012;97:1836-1843. doi: 10.1210/jc.2012-1852.
  47. Belaya ZE, Iljin AV, Melnichenko GA et al. Diagnostic performance of late- night salivary cortisol measured by automated electrochemiluminescence immunoassay in obese and overweight patients referred to exclude Cushing’s syndrome. Endocrine. 2012;41:494-500. doi: 10.1007/s12020- 012-9658-3.
  48. Белая ЖЕ, Ильин АВ, Мельниченко ГА и др. Определение уровня кортизола в слюне на автоматическом иммунохимическом анализаторе Cobas E601 (“Roche”) для диагностики эндогенного гиперкортицизма среди пациентов с ожирением. Клиническая лабораторная диагностика. 2011;(12):7-12.
  49. Инструкция по определению кортизола in vitro в сыворотке, плазме крови, моче и слюне человека, каталожный номер 11875116122 для анализаторов Elecsys 1010, Elecsys 2010, Modular Analytics E170, Cobas e411, Cobas e601
  50. Jeyaraman K, Amini AC, Nandita G, Dwivedi SN. Late-night salivary cortisol in normal subjects and in patients with Cushing’s syndrome. Postgraduate Medicine Journal. 2010;86:399-404. doi: 10.1136/pgmj.2009.090787.
  51. Vogeser M, Durner J, Seliger E, Auernhammer C. Measurement of late- night salivary cortisol with an automated immunoassay system. Clinical Chemistry and Laboratiry Medicine. 2006;44:1441-1445.
  52. Belaya ZE, Melnichenko GA. Practical evaluation of late-night salivary cortisol: a real-life approach. Endocrine. 2012;42:222-223. doi: 10.1007/s12020-012-9709-9.
  53. Белая ЖЕ, Рожинская ЛЯ, Мельниченко ГА и др. Современный взгляд на скрининг и диагностику эндогенного гиперкортицизма. Проблемы эндокринологии. 2012;(58):35-41.
  54. Aniszewski JP, Young MF, Thompson GB et al. Cushing syndrome due to ectopic adrenocorticotropic hormone secretion. World J Surgery. 2001;25:934-940.
  55. Wajchenberg BL, Liberman B, Giannella Neto D et al. Growth hormone axis in Cushing’s syndrome. Horm Res. 1996;45:99-107.
  56. Ilias I, Torpy DJ, Pacak K et al. Cushing’s syndrome due to ectopic corticotrophin secretion: twenty years’ experience at the National Institutes of Health. Clin Endocrinol Metab. 2005;90:4955-4962.
  57. Lad SP, Path CG, Laws ER, Katznelson L. The role of inferior petrosal sinus sampling in the diagnostic localization of Cushing’s disease. Neurosurg Focus. 2007;23:1-6.
  58. Utz A, Biller BMK. The role of bilateral inferior petrosal sinus sampling in the diagnosis of Cushing’s syndrome. Arq Bras Endocrinol Metab. 2007;51:1329-1338.
  59. Katznelson L, Bogan JS, Trob JR et al. Biochemical assessment of Cushing’s disease in patients with corticotroph macroadenomas. Clin Endocrinol Metab. 1998;83:1619-1623.
  60. Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states. Edocr Rev. 1998;19:647-672.
  61. Finding JW, Raff H. Screening and diagnosis of Cushing’s syndrome. Endocrinol Metabolism Clin North Am. 2005;38:385-402.
  62. Hall WA, Luciano MG, Doppman JL et al. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Annual Internal Medicine. 1994;120:817-820.
  63. Coulon G, Fellman D, Arbez-Gindre F, Pageaut G. Latent pituitary adenoma. Autopsy study. Sem Hop. 1983;59:2747-2750.
  64. Дедов ИИ, Белая ЖЕ, Ситкин ИИ и др. Значение метода селективного забора крови из нижних каменистых синусов в дифференциальной диагностике АКТГ-зависимого гиперкортицизма. Проблемы Эндокринологии. 2009;(55):35-40.
  65. Ezzat S, Asa SL, Couldwell WT et al. The prevalence of pituitary adenomas: a systematic review. Cancer. 2004;101:613-619.
  66. Ilias I, Chang R, Pacak K et al. Jugular venous sampling: An alternative to petrosal sinus sampling for the diagnostic evaluation of adrenocorticotropic hormone-dependent Cushing syndrome. Clin Endocrinol Metab. 2004;89:3795-3800.
  67. Isidori AM, Kaltsas GA, Pozza C et al. The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow- up. Clin Endocrinol Metab. 2006;91:371-377.
  68. Oldfield EH, Girton ME, Doppman JL. Absence of intercavernous venous mixing: evidence supporting lateralization of pituitary microadenomas by venous sampling. Clin Endocrinol Metab. 1985;61:644-647.
  69. Oldfield EH, Chrousos GP, Schulte HM et al. Preoperative lateralization of ACTH-secreting pituitary microadenomas by bilateral and simultaneous inferior petrosal venous sinus sampling. New England J Medicine. 1985;312:100-103.
  70. Дедов ИИ, Ситкин ИИ, Белая ЖЕ. Первый опыт использования селективного забора крови из нижних каменистых синусов в России (клиническое наблюдение). Проблемы эндокринологии. 2009;(55):11- 16.
  71. Рожинская ЛЯ, Белая ЖЕ, Ситкин ИИ и др. Возможности забора крови из нижних каменистых синусов в дифференциальной диагностике АКТГ-зависимого гиперкортицизма. Сборник тезисов Всероссийский конгресс «Современные технологии в эндокринологии». 2009;126.
  72. Белая ЖЕ, Рожинская ЛЯ, Ситкин ИИ и др. Клинический случай АКТГ-эктопированного синдрома». Вестник РОНЦ им. Н.Н.Блохина РАМН. 2010;21(4):46-51.
  73. Ситкин ИИ, Белая ЖЕ, Рожинская ЛЯ и др. Двухсторонний селективный забор крови из нижних каменистых синусов на фоне стимуляции десмопрессином в дифференциальной диагностике АКТГ- зависимого гиперкортицизма. Диагностическая и интервенционная радиология. 2013;7(3):57-68.
  74. Древаль АВ, Комердус ИВ, Мурзина АВ и др. Селективный забор крови из нижних каменистых синусов в дифференциальной диагностике АКТГ-зависимого гиперкортицизма (собственный клинический опыт). Проблемы Эндокринологии. 2012;(58):29-33.
  75. Yanovski J, Cutler G J, Doppman J et al. The limited ability of inferior petrosal sinus sampling with corticotrophin releasing hormone to distinguish Cushing’s disease from pseudo-Cushing states or normal physiology. Clin Endocrinol Metab. 1993;77:503-509.
  76. Heaney AP, Melmed S. Molecular targets in pituitary tumors. Nat Rev Cancer. 2004;4:285-295.
  77. Findling JW, Kehoe ME, Raff H. Identification of patients with Cushing’s disease with negative pituitary adrenocorticotropin gradients during inferior petrosal sinus sampling: Prolactin as an index of pituitary venous effluent. Clin Endocrinol Metab. 2004;89(12):6005-6009.
  78. Белая ЖЕ, Рожинская ЛЯ, Мельниченко ГА и др. Роль градиента пролактина и АКТГ/пролактин нормализованного отношения для повышения чувствительности и специфичности селективного забора крови из нижних каменистых синусов для дифференциальной диагностики АКТГ-зависимого гиперкортицизма. Проблемы Эндокринологии. 2013;59(4):3-10.
  79. Belaya Z, Sitkin I, Rozhinskaya L et al. Usefulness of Prolactin IPS/P ratio and dominant ACTH/Prolactin ratio in bilateral inferior petrosal sinus sampling with desmopressin stimulation in patients with ACTH-dependent Cushing’s syndrome. Austrian J Clinical Endocrinology and Metabolism. 2012;5(3):21.
  80. Белая ЖЕ, Драгунова НВ, Рожинская ЛЯ и др. Низкотравматичные переломы у пациентов с эндогенным гиперкортицизмом. Предикторы и факторы риска, влияние на качество жизни. Остеопороз и остеопатии. 2013;(1):7-13.
  81. Belaya ZE, Rozhinskaya LY, Solodovnikov AG et al. Glucocorticoid- induced osteoporosis: fractures and bone remodeling in patients with endogenous Cushing’s syndrome. Series: Endocrinology Research and Clinical Developments. Online Book, Published by Nova Science Publishers, Inc New-York. 2013, 55 pp; ISBN: 978-1-62948-341-2, online book
  82. Lindsay JR, Jonklaas J, Oldfield EH, Nieman LK. Cushing’s syndrome during pregnancy: personal experience and review of the literature. Clin Endocrinol Metab. 2005;90:3077-3083.
  83. Гринева ЕН. Заболевания гипофиза и беременность. Бюллетень Федерального Центра сердца, крови и эндокринологии им. В.А. Алмазова. 2013;(2):23-28.
  84. Molitich ME. Pituitary tumors and pregnancy. GH IGF Res. 2003;13:38-44. 85.Pivonello R, De Martino MC, Auriemma RS et al. Pituitary tumors and pregnancy: the interplay between a pathologic condition and a physiologic status. Endocrinol Invest. 2014;37:99-112. doi: 10.1007/s40618-013-0019-8. 86.Aron DC, Schnall AM, Sheeler LR. Cushing’s syndrome in pregnancy. Obstet Gynecol. 1990;162:244-252.
  85. Colao A, Boscaro M, Ferone D, Casanueva FF. Managing Cushing’s disease: the state of the art. Endocrine. 2014 Sep;47(1):9-20. doi: 10.1007/s12020-013-0129-2.
  86. Leach P, Abou-Zeid AH, Kearney T et al. Endoscopic transsphenoidal pituitary surgery: evidence of an operative learning curve. Neurosurgery. 2010;67:1205-1212. doi: 10.1227/NEU.0b013e3181ef25c5.
  87. Bertagna X, Guignat L. Approach to the Cushing’s disease patient with persistent/recurrent hypercortisolism after pituitary surgery. Clinical Endocrinology Metabolism. 2013;98:1205-1212. doi: 10.1210/jc.2012-3200. 90.Boscaro M, Barzon F, Fallo F. Cushing’s syndrome. Lancet. 2001;357(9258):783-791.
  88. 91.Mampalam TJ, Tyrrell JB, Wilson CB. Transsphenoidal microsurgery for Cushing disease. A report of 216 cases. Ann Intern Med. 1988;109:487–493. 92.Григорьев АЮ, Азизян ВН, Иващенко ОВ, Надеждина ЕЮ. Повторная транссфеноидальная аденомэктомия при рецидиве и персистирующем течении болезни Иценко-Кушинга. Нейрохирургия. 2014;2:49-53.
  89. Friedman RB, Oldfield LK, Nieman. Repeat transsphenoidal surgery for Cushing’s disease. Neurosurgery. 1989;71:520-527.
  90. Benvensite RJ, King WA, Walsh J et al. Repeated transsphenoidal surgery to treat recurrent or residual pituitary adenoma. Neurosurg. 2005;102,:1004- 1012.
  91. Chee GH, Mathias DB, James RA, Kendall-Taylor P. Transsphenoidal pituitary surgery in Cushing’s disease: can we predict outcome? Clin Endocrinol (Oxf). 2001;54:617–626.
  92. Atkinson AB, Kennedy A, Wiggam MI et al. Long-term remission rates after pituitary surgery for Cushing’s disease: the need for long-term surveillance. Clin Endocrinol (Oxf). 2005;63:549–559.
  93. Chen JC, Amar AP, Choi S et al. Transsphenoidal microsurgical treatment of Cushing disease: postoperative assessment of surgical efficacy by application of an overnight low-dose dexamethasone suppression test. Neurosurg. 2003;98:967–973.
  94. Esposito F, Dusick JR, Cohan P et al. Clinical review: early morning cortisol levels as a predictor of remission after transsphenoidal surgery for Cushing’s disease. Clin Endocrinol Metab. 2006;91:7–13.
  95. Estrada J, Garcia-Uria J, Lamas C et al. The complete normalization of the adrenocortical function as the criterion of cure after transsphenoidal surgery for Cushing’s disease. Clin Endocrinol Metab. 2001;86:5695–5699.
  96. Hammer GD, Tyrrell JB, Lamborn KR et al. Transsphenoidal microsurgery for Cushing’s disease: initial outcome and long-term results. Clin Endocrinol Metab. 2004;89:6348–6357.
  97. Pereira AM, van Aken MO, van Dulken H et al. Long-term predictive value of postsurgical cortisol concentrations for cure and risk of recurrence in Cushing’s disease. Clin Endocrinol Metab. 2003;88:5858–5864.
  98. Rees DA, Hanna FW, Davies JS et al. Long-term follow-up results of transsphenoidal surgery for Cushing’s disease in a single centre using strict criteria for remission. Clin Endocrinol (Oxf). 2002;56:541–551.
  99. Yap LB, Turner HE, Adams CB, Wass JA. Undetectable postoperative cortisol does not always predict long-term remission in Cushing’s disease: a single centre audit. Clin Endocrinol (Oxf). 2002;56:25– 31.
  100. Sonino N, Zielezny M, Fava GA et al. Risk factors and long-term outcome in pituitary-dependent Cushing’s disease. Clin Endocrinol Metab. 1996;81:2647-2652.
  101. Bruns C, Lewis I, Briner U et al. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002 May;146(5):707-716.
  102. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev. 2003;24:28-47.
  103. Colao A, Petersenn S, Newell-Price J et al. A 12-month phase 3 study of Pasireotide in Cushing’s disease. NEJM. 2012;366:914-924. doi: 10.1056/NEJMoa1105743.
  104. Pivonello R, Arnaldi G, Scaroni C et al. Effectiveness of pasireotide treatment in patients with Cushing’s disease: a national experience based on clinical practice. ENEA 2014;page 56, Abstract ID: 467, Sofia, Bulgaria,
  105. MacKenzie Feder J, Bourdeau I, Vallette S et al. Pasireotide monotherapy in Cushing’s disease: a single-centre experience with 5-year extension of phase III trial. Pituitary. 2014 Dec;17(6):519-29. doi: 10.1007/s11102-013-0539-4.
  106. Henry RR, Mudaliar S, Hermosillo Reséndiz K et al. Mechanism and management of hyperglycemia associated with pasireotide: results from studies in healthy volunteers. Endocr Abstr. 2011;26:26.
  107. Reznik AY, Bertherat J, Borson-Chazot F et al. Management of hyperglycaemia in Cushing’s disease: Experts’ proposals on the use of pasireotide. Diabetes and Metabolism. 2013;39:34–41. doi: 10.1016/j.diabet.2012.10.005.
  108. Colao A, Block CD, Caztambide MS et al. Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations. Pituitary. 2014 Apr;17(2):180-6. doi: 10.1007/s11102- 013-0483-3.
  109. Godbout A, Manavela MP, Danilowicz K et al. Cabergoline monotherapy in the long-term treatment of Cushing’s disease. European J Endocrinology. 2010;163:709-716. doi: 10.1530/EJE-10-0382.
  110. Lila AR, Gopal RA, Acharya SV. Efficacy of cabergoline in uncured (persistent or recurrent) Cushing disease after pituitary surgical treatment with or without radiotherapy. Endocrine Practice. 2010;16:968-976. doi: 10.4158/EP10031.OR.
  111. Pivonello R, De Martino MC, Cappabianca P et al. The medical treatment of Cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery.Clinical Endocrinology and Metabolism. 2009;94:223-230. doi: 10.1210/jc.2008-1533.
  112. Fleseriu M, Biller BMK, Findling JW et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s Syndrome. JCEM. 2012;97:2039-2049. doi: 10.1210/jc.2011-3350.
  113. Gadelha MR, Neto LV. Efficacy of medical treatment in Cushing’s disease: a systematic review. Clinical Endocrinology. 2014;80:1-12. doi: 10.1111/cen.12345.
  114. Mackley HB, Reddy CA, Lee SY et al. Intensity-modulated radiotherapy for pituitary adenomas. The preliminary report of the Cleveland Clinic experience. Int J Radiat Oncol Biol Phys. 2007;67:232-239.
  115. Kumar S, Burke K, Nalder C et al. Treatment accuracy of fractionated stereotactic radiotherapy. Radiother Oncol. 2005;74:53-59.
  116. Ding D, Starke R, Sheehan J. Treatment paradigms for pituitary adenomas: defining the roles of radiosurgery and radiation therapy. Neurooncol. 2014;117:445–457.
  117. Jagannathan J, Sheehan JP, Pouratian N et al. Gamma Knife surgery for Cushing’s disease. Neurosurg. 2007;106(6):980–987.
  118. Марова ЕИ, Манченко ОВ, Воронцов АВ и др. Опыт радиохирургического лечения пациентов с болезнью Иценко-Кушинга без выявленной аденомы гипофиза. Проблемы эндокринологии. 2008;(3):21-27.
  119. Leenstra J, Shota T, Kline R. Factors associated with endocrine deficit after SRS of pituitary adenomas. Neurosurgery. 2010;1:27-30. doi: 10.1227/01.NEU.0000370978.31405.A9.
  120. Tsang RW, Brierley JD, Panzarella T et al. Radiation therapy for pituitary adenoma. Treatment outcome and prognostic factors. Int J Radiat Oncol Biol Phys. 1994;30:557-565.
  121. Becker G, Kocher M, Kortmann RD et al. Radiation therapy in the multimodal treatment approach of pituitary adenomas. Strahlenther Onkol. 2002;178:173-186.
  122. Laws ER, Sheehan JP, Sheehan JM et al. Stereotactic radiosurgery for pituitary adenomas. A review of the literature. Neurooncol. 2004;69:257- 272.
  123. Rowe J, Grainger A, Walton L et al. Risk for malignancy after gamma knife stereotactic radiosurgery. Neurosurgery. 2007;60:60-66.
  124. Morris LF, Harris RS, Milton DR et al. Impact and timing of bilateral adrenalectomy for refractory adrenocorticotropic hormone – dependent Cushing’s syndrome. Surgery. 2013;154:1174-1184.
  125. Ritzel K, Beuschlein F, Mickish A et al. Outcome of bilateral adrenalectomy in Cushing’s syndrome: a systematic review. JCEM. 2013;98:3939- 3948. doi: 10.1210/jc.2013-1470.

Для продолжения работы требуется вход / регистрация